Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDX
· Real-Time Price · USD
18.77
-0.85 (-4.33%)
At close: May 14, 2025, 1:56 PM
Celldex Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Grant Revenue | 7.01M | 6.61M | 2.3M | 5.12M | 473K | 3.34M |
| Grant Revenue Growth | +6.09% | +187.05% | -55.03% | +981.82% | -85.84% | n/a |
| Service Revenue | 13K | 278K | 56K | 2.3M | 3.1M | 6.2M |
| Service Revenue Growth | -95.32% | +396.43% | -97.57% | -25.77% | -49.98% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 10.26M | 10.05M | 9.13M | 9.1M | 8.83M | 8.22M | 7.22M | 6.64M | 6.6M | 6.53M | 7.15M | 6.91M | 6.24M | 5.82M | 4.31M | 4.12M | 3.62M | 3.64M | 3.53M | 3.67M | 3.22M | 3.4M | 3.91M | 4.9M | 4.33M | 3.72M | 5.62M | 5.59M | 5.89M | 5.35M | 6.53M | 7.23M | 11.93M | 6.95M | 7.79M | 9.31M | 11.07M | 8.49M | 8.18M | 6.09M |
| Selling, General, and Administrative Revenue Growth | +2.08% | +10.14% | +0.27% | +3.07% | +7.43% | +13.85% | +8.75% | +0.64% | +1.03% | -8.71% | +3.52% | +10.74% | +7.22% | +35.18% | +4.49% | +13.75% | -0.47% | +3.17% | -3.76% | +13.89% | -5.41% | -12.92% | -20.18% | +13.02% | +16.39% | -33.78% | +0.50% | -5.11% | +10.25% | -18.18% | -9.61% | -39.42% | +71.70% | -10.78% | -16.30% | -15.96% | +30.49% | +3.70% | +34.41% | n/a |
| Research and Development Revenue | 46.12M | 3K | 38.89M | 30.89M | 29.67M | 34.53M | 26.25M | 26.8M | 22.9M | 21.57M | 20.73M | 17.06M | 14.68M | 13.56M | 12.36M | 12.72M | 10.43M | 10.71M | 9.71M | 11.7M | 10.34M | 11.1M | 10.08M | 11.15M | 11.21M | 11.92M | 21.45M | 21.88M | 23.46M | 21.91M | 25M | 25.79M | 24.56M | 25.01M | 25.71M | 27.45M | 23.9M | 24.66M | 26.49M | 25.13M |
| Research and Development Revenue Growth | +1537233.33% | -99.99% | +25.91% | +4.11% | -14.10% | +31.55% | -2.04% | +17.02% | +6.16% | +4.06% | +21.55% | +16.20% | +8.27% | +9.72% | -2.86% | +22.01% | -2.64% | +10.33% | -17.02% | +13.12% | -6.86% | +10.12% | -9.60% | -0.50% | -5.97% | -44.43% | -1.95% | -6.77% | +7.07% | -12.34% | -3.08% | +5.03% | -1.80% | -2.73% | -6.32% | +14.84% | -3.07% | -6.92% | +5.43% | n/a |